부산대학교 도서관

BACKGROUND: Though human papillomavirus (HPV)-related lesions in the neovagina of transgender women have been well documented, information around high risk HPV in the neovagina have been very limited. The objective of this study was to determine hrHPV DNA detection rate in the neovagina of transgender women. METHODS: Neovaginal and anal swab were collected in liquid-based cytology fluid from transgender women visiting Gender-Health Clinic and Tangerine Community Health Clinic in Bangkok, Thailand. Samples were processed by for hrHPV DNA (reported as subtype 16, 18 or pooled result of 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66) by automated real-time PCR and for neovaginal cytology according to the Bethesda system. Demographic data and sexual history were obtained, physical examination was conducted. HIV status was obtained from existing medical records. RESULTS: Samples were collected from 57 transgender women (mean age 30.4 years, [IQR = 8]). From 35 valid out of 57 neovaginal samples, 8 (20%) tested positive for hrHPV DNA. From 30 valid out of 57 anal samples, 6 (19.4%) tested positive for hrHPV DNA. HIV status was known for 52 transgender women, 1 of which were HIV-infected; neovaginal hrHPV was invalid in that patient. CONCLUSIONS: One out of five transgender women visiting sexual health clinics in Bangkok was found to have hrHPV DNA in neovaginal and anal compartments. Studies are needed to look at incidence and persistence of hrHPV infection to inform ano-genital precancerous and cancerous screening programs for transgender women